Gene therapy trial aims to boost HIV fight in lymphoma patients
NCT ID NCT02337985
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether giving gene therapy after chemotherapy is safe for people with AIDS-related non-Hodgkin lymphoma. The gene therapy adds special anti-HIV genes to the patient's own blood stem cells to help the body fight HIV. Ten participants will receive the treatment, and researchers will monitor side effects and check if the gene therapy works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIDS-RELATED BURKITT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NCI Lymphoid Malignancies Branch
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Smart pill bottles and health coaches team up to tackle HIV in the deep south
- Can one Mega-Dose of an antifungal beat a deadly infection in AIDS patients?
- Can Long-Acting HIV shots outperform daily pills during lymphoma treatment?
- Immune-Boosting cocktail aims to free HIV patients from daily medication